Harrow
HROW
30.41
-1.72
-5.35%
Harrow
US · HROW
#3155 by market cap
30.41
-1.72
-5.35%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Harrow
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.
- Founded
- 2006
- CEO
- Mr. Mark L. Baum
- Employees
- 373
- Headquarters
- Nashville, Tennessee, United States of America
- Fiscal year end
- 12-31
- Website
- harrow.com
Company profile
- Exchange
- US
- Symbol
- HROW
- Market-cap rank
- #3155
- Market cap
- 1.14B
- Float cap
- 860.08M
- Shares out
- 37.53M
- Float shares
- 28.28M
Sectors & themes
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Harrow discussion 0 comments